Screener / SEC EDGAR /CIK 0001588978 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

PROCEPT BioRobotics Corp PRCT

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What PRCT's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms

Open on SEC

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance SAN JOSE, Calif., November 4, 2026 -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.

“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan,” said Larry Wood, Chief Executive Officer. “Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027. We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”

Wood continued, “This quarter, we continued expanding our installed base and drove strong utilization in HYDROS® accounts. We delivered approximately 18% revenue growth and 22% U.S. procedure growth while accelerating our replacement cycle to transition AquaBeam systems to HYDROS.”

• Total revenue of $98.3 million for the third quarter of 2026, an increase of 18% compared to the prior year period in 2025

• U.S. procedures over 13,400 for the third quarter of 2026, an increase of approximately 22% compared to the prior year period

• U.S. handpieces sold as percent of U.S. procedures in the third quarter of 2026 was approximately 106%

• Third quarter of 2026 handpiece average selling price of approximately $3,570 increased 12% compared to the third quarter of 2025

• International revenue of $12.5 million for the third quarter of 2026, an increase of 32% compared to the prior year period

• Gross margin of 66% for the third quarter of 2026, compared to 65% in the prior year period.

Total revenue for the third quarter of 2026 was $98.3 million, an increase of 18% compared to the prior year period. The increase was driven by increased U.S. handpiece and system revenue and international revenue. U.S. revenue was $85.8 million, representing growth of 16% compared to the prior year period. U.S. handpiece and consumable revenue for the third quarter of 2026 was $53.9 million, an increase of 21% compared to the prior year period. U.S. system revenue for the third quarter of 2026 was $24.7 million, flat compared to the prior year period. International revenue was $12.5 million for the quarter, an increase of 32% compared to the prior year period.

Gross margin for the third quarter of 2026 was 66% compared to 65% in the prior year period.

Operating expenses in the third quarter of 2026 were $92.5 million, compared with $77.2 million in the prior year period. The increase in operating expenses reflects continued investment in our people, product development, clinical studies and sales and marketing programs.

Net loss was $26.5 million for the third quarter of 2026, compared to a loss of $21.4 million in the prior year period. Adjusted EBITDA* was a loss of $9.8 million for the third quarter of 2026, compared to a loss of $7.4 million in the prior year period.

Cash, cash equivalents and restricted cash balances as of September 30, 2026, totaled approximately $221.4 million.

• The Company reiterates revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period

• The Company reiterates U.S. procedure volume for the full year 2026 to be in the range of 54,000-56,000 which represents growth of 25% to 29% compared to the prior year period

• The Company reiterates gross margin for the full year 2026 to be approximately 65%

• The Company reiterates adjusted EBITDA* loss for the full year 2026 to be in the range of $35 million to $30 million

*Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).

PROCEPT BioRobotics will host a conference call to discuss the third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the links below:

◦ https://register-conf.media- server.com/register/BIac4b002880274c7086f519f21b93cd1f

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM ® and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.

The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.

This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2026, statements regarding the potential utilities, values, benefits and advantages of Aquablation therapy performed using PROCEPT BioRobotics’ products, including AquaBeam or Hydros Robotic Systems, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on the Company’s current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which the Company is not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, procedure growth, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margins, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 26, 2026, and subsequent quarterly reports on Form 10-Q. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward- looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.

All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 218,369 $ 286,503 Accounts receivable, net 105,030 83,533 Inventory 81,410 70,694 Prepaid expenses and other current 9,381 9,648 assets Total current assets 414,190 450,378 Restricted cash, 3,038 3,038 non-current Property and equipment, net 30,165 30,399 Operating lease 16,373 17,538 right-of-use assets, net Intangible assets, net 502 709 Other assets 9,491 6,019 Total assets $ 473,759 $ 508,081 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 16,721 $ 17,285 Accrued compensation 25,976 23,175 Deferred revenue 15,636 13,048 Operating leases, current 2,655 2,214 Other current liabilities 9,365 10,073 Total current liabilities 70,353 65,795 Long-term debt 51,767 51,615 Operating leases, 22,570 24,654 non-current Other non-current 161 147 liabilities Total liabilities 144,851 142,211 Stockholders’ equity: Additional paid-in capital 1,055,475 1,007,390 Accumulated other 5 37 comprehensive gain Accumulated deficit -726,572 -641,557 Total stockholders’ equity 328,908 365,870 Total liabilities and stockholders’ $ 473,759 $ 508,081 equity

Full text with the tables
 PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 
                            2026 Financial Guidance                             
SAN JOSE, Calif., November 4, 2026 -- PROCEPT BioRobotics® Corporation (Nasdaq:
PRCT) (the “Company”), a surgical robotics company focused on advancing patient
care by developing transformative solutions in urology, today reported unaudited
financial results for the quarter ended September 30, 2026.

“As we enter the fourth quarter, we remain focused on executing against our
full-year revenue guidance and profitability plan,” said Larry Wood, Chief
Executive Officer. “Further, we remain excited to present data from WATER IV,
our randomized trial comparing Aquablation to radical prostatectomy in prostate
cancer, on track for the first half of 2027. We see significant opportunity and
a clear path to achieving durable growth and profitability ahead.”

Wood continued, “This quarter, we continued expanding our installed base and
drove strong utilization in HYDROS® accounts. We delivered approximately 18%
revenue growth and 22% U.S. procedure growth while accelerating our replacement
cycle to transition AquaBeam systems to HYDROS.”
                                                                                
  Third Quarter 2026 Financial Results                                          
                                                                                
• Total revenue of $98.3 million for the third quarter of 2026, an increase of
18% compared to the prior year period in 2025

• U.S. procedures over 13,400 for the third quarter of 2026, an increase of
approximately 22% compared to the prior year period

• Delivered 62 U.S. HYDROS systems, which included 20 replacement systems. U.S.
average selling price was approximately $495,000 for new HYDROS systems

• U.S. handpieces sold as percent of U.S. procedures in the third quarter of
2026 was approximately 106%

• Third quarter of 2026 handpiece average selling price of approximately $3,570
increased 12% compared to the third quarter of 2025

• International revenue of $12.5 million for the third quarter of 2026, an
increase of 32% compared to the prior year period

• Gross margin of 66% for the third quarter of 2026, compared to 65% in the
prior year period.

Total revenue for the third quarter of 2026 was $98.3 million, an increase of
18% compared to the prior year period. The increase was driven by increased U.S.
handpiece and system revenue and international revenue. U.S. revenue was $85.8
million, representing growth of 16% compared to the prior year period. U.S.
handpiece and consumable revenue for the third quarter of 2026 was $53.9
million, an increase of 21% compared to the prior year period. U.S. system
revenue for the third quarter of 2026 was $24.7 million, flat compared to the
prior year period. International revenue was $12.5 million for the quarter, an
increase of 32% compared to the prior year period.

Gross margin for the third quarter of 2026 was 66% compared to 65% in the prior
year period.

Operating expenses in the third quarter of 2026 were $92.5 million, compared
with $77.2 million in the prior year period. The increase in operating expenses
reflects continued investment in our people, product development, clinical
studies and sales and marketing programs.

Net loss was $26.5 million for the third quarter of 2026, compared to a loss of
$21.4 million in the prior year period. Adjusted EBITDA* was a loss of $9.8
million for the third quarter of 2026, compared to a loss of $7.4 million in the
prior year period.

Cash, cash equivalents and restricted cash balances as of September 30, 2026,
totaled approximately $221.4 million.
                                                                                
  Full Year 2026 Financial Guidance                                             
                                                                                
• The Company reiterates revenue for the full year 2026 to be in the range of
$390 million to $410 million, which represents growth of 27% to 33% compared to
the prior year period

• The Company reiterates U.S. procedure volume for the full year 2026 to be in
the range of 54,000-56,000 which represents growth of 25% to 29% compared to the
prior year period

• The Company reiterates gross margin for the full year 2026 to be approximately
65%

• The Company reiterates adjusted EBITDA* loss for the full year 2026 to be in
the range of $35 million to $30 million

*Adjusted EBITDA is a financial measure that is not prepared in accordance with
generally accepted accounting principles in the United States (GAAP). For more
information about the Company’s use of non-GAAP financial measures, please see
the section below titled “Use of Non-GAAP Financial Measures (Unaudited).
                                                                                
  Webcast and Conference Call Information                                       
                                                                                
PROCEPT BioRobotics will host a conference call to discuss the third quarter
2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern
Time.

Investors interested in listening to the conference call may do so by following
one of the links below:

• Webcast link for interested listeners:

◦ https://edge.media-server.com/mmc/p/rdtftqik/

• Dial-in registration for sell-side research analysts:

◦ https://register-conf.media-
server.com/register/BIac4b002880274c7086f519f21b93cd1f
                                                                                
  About PROCEPT BioRobotics Corporation                                         
                                                                                
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient
care by developing transformative solutions in urology. PROCEPT BioRobotics
manufactures the AQUABEAM ® and HYDROS Robotic Systems. The HYDROS Robotic
System is the only AI-powered, robotic technology that delivers Aquablation
therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective,
safe, and durable outcomes for males suffering from lower urinary tract symptoms
or LUTS, due to BPH that are independent of prostate size and shape or surgeon
experience. BPH is the most common prostate disease and impacts approximately 40
million men in the United States. The Company has developed a significant and
growing body of clinical evidence with approximately 250 peer-reviewed
publications, supporting the benefits and clinical advantages of Aquablation
therapy.
                                                                                
  Use of Non-GAAP Financial Measures                                            
                                                                                
(Unaudited)

This press release references Adjusted EBITDA, a financial measure that is not
prepared in accordance with generally accepted accounting principles in the
United States (GAAP). The Company defines Adjusted EBITDA as earnings before
interest expense, taxes, depreciation and amortization and stock-based
compensation. Non-GAAP financial measures are not a substitute for or superior
to measures of financial performance prepared in accordance with GAAP and should
not be considered as an alternative to any other performance measures derived in
accordance with GAAP.

The Company believes that presenting Adjusted EBITDA provides useful
supplemental information to investors about the Company in understanding and
evaluating its operating results, enhancing the overall understanding of its
past performance and future prospects, and allowing for greater transparency
with respect to key financial metrics used by its management in financial and
operational decision making. However, there are a number of limitations related
to the use of non-GAAP measures and their nearest GAAP equivalents. For example,
other companies may calculate non-GAAP measures differently, or may use other
measures to calculate their financial performance, and therefore any non-GAAP
measures the Company uses may not be directly comparable to similarly titled
measures of other companies.
                                                                                
  Forward Looking Statements                                                    
                                                                                
This release contains forward‐looking statements within the meaning of federal
securities laws, including with respect to the Company’s projected financial
performance for full year 2026, statements regarding the potential utilities,
values, benefits and advantages of Aquablation therapy performed using PROCEPT
BioRobotics’ products, including AquaBeam or Hydros Robotic Systems, which
involve risks and uncertainties that could cause the actual results to differ
materially from the anticipated results and expectations expressed in these
forward-looking statements. You are cautioned not to place undue reliance on
these forward-looking statements. Forward-looking statements are only
predictions based on the Company’s current expectations, estimates, and
assumptions, valid only as of the date they are made, and subject to risks and
uncertainties, some of which the Company is not currently aware. Forward-looking
statements may include statements regarding financial guidance, market
opportunity and penetration, procedure growth, the Company’s possible or assumed
future results of operations, including descriptions of the Company’s revenues,
gross margins, profitability, operating expenses, installed base growth,
commercial momentum and overall business strategy. Forward‐looking statements
should not be read as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which such
performance or results will be achieved. These forward‐looking statements are
based on the Company’s current expectations and inherently involve significant
risks and uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward‐looking statements as a result
of these risks and uncertainties. These risks and uncertainties are described
more fully in the section titled “Risk Factors” in the Company’s filings with
the Securities and Exchange Commission (the “SEC”), including the Company’s
annual report on Form 10-K filed with the SEC on February 26, 2026, and
subsequent quarterly reports on Form 10-Q. PROCEPT BioRobotics does not
undertake any obligation to update forward‐looking statements and expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward‐looking statements contained herein. These forward-
looking statements should not be relied upon as representing PROCEPT
BioRobotics’ views as of any date subsequent to the date of this press release.
                                                                                
  Important Safety Information                                                  
                                                                                
All surgical treatments have inherent and associated side effects. For a list of
potential side effects visit https://aquablation.com/safety-information/

Media Contact: Pooja Rao, [email protected]

Investor Contact: Marissa Bych, [email protected]
                                                                                
                        PROCEPT BioRobotics Corporation                         
                                                                                
                                                                                
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                 
                                                                                
                (Unaudited, in thousands, except per share data)                
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Revenue    $      98,291    $      83,327    $      275,922    $     231,671  
  Cost of           33,143           29,321            94,447           81,758  
  sales                                                                         
  Gross             65,148           54,006           181,475          149,913  
  profit                                                                        
  Operat…                                                                       
  expens…                                                                       
  Resear…                                                                       
  and               20,011           18,187            61,578           52,221  
  develo…                                                                       
  Sellin…                                                                       
  general           72,513           59,011           207,269          170,510  
  and                                                                           
  admini…                                                                       
  Total                                                                         
  operat…           92,524           77,198           268,847          222,731  
  expens…                                                                       
  Loss                                                                          
  from             -27,376          -23,192           -87,372          -72,818  
  operat…                                                                       
  Intere…             -856             -919            -2,516           -2,692  
  expense                                                                       
  Intere…                                                                       
  and                                                                           
  other              1,658            2,734             4,866            9,905  
  income,                                                                       
  net                                                                           
  Loss                                                                          
  before           -26,574          -21,377           -85,022          -65,605  
  income                                                                        
  taxes                                                                         
  Provis…                                                                       
  for                                                                           
  (benef…              -58               34                -7              122  
  from)                                                                         
  income                                                                        
  taxes                                                                         
  Net        $     -26,516    $     -21,411    $      -85,015    $     -65,727  
  loss                                                                          
  Net                                                                           
  loss                                                                          
  per                                                                           
  share,     $       -0.46    $       -0.38    $        -1.49    $       -1.19  
  basic                                                                         
  and                                                                           
  diluted                                                                       
  Weight…                                                                       
  common                                                                        
  shares                                                                        
  used to                                                                       
  Compute                                                                       
  net                                                                           
  loss                                                                          
  per                                                                           
  share                                                                         
  attrib…                                                                       
  to                                                                            
  Common                                                                        
  shareh…                                                                       
  basic             57,326           55,727            56,971           55,366  
  and                                                                           
  diluted                                                                       
                                                                                
                                                                                
                        PROCEPT BioRobotics Corporation                         
                                                                                
                                                                                
               RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA               
                                                                                
                           (Unaudited, in thousands)                            
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                   Septem…                           Septemb…                   
             2026      30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net        $     -26,516    $     -21,411    $      -85,015    $     -65,727  
  loss                                                                          
  Deprec…                                                                       
  and                2,539            1,619             6,264            4,681  
  amorti…                                                                       
  expense                                                                       
  Stock-…                                                                       
  compen…           15,080           14,490            42,686           36,761  
  expense                                                                       
  Intere…                                                                       
  (incom…                                                                       
  and                 -925           -2,093            -3,209           -6,913  
  intere…                                                                       
  expens…                                                                       
  net                                                                           
  Adjust…    $      -9,822    $      -7,395    $      -39,274    $     -31,198  
  EBITDA                                                                        
                                                                                
                                                                                
                        PROCEPT BioRobotics Corporation                         
                                                                                
        RECONCILIATION OF GAAP NET LOSS TO ADJUSTED 2026 EBITDA Guidance        
                                                                                
                           (Unaudited, in thousands)                            
                                                                                
                          For the Year Ending                                   
                          December 31, 2026                                     
 ────────────────────────────────────────────────────────────────────────────── 
                                                 LOW             HIGH           
  Net loss                                       $    -97,800    $     -92,800  
  Depreciation and                                      8,800            8,800  
  amortization expense                                                          
  Stock-based                                          58,200           58,200  
  compensation expense                                                          
  Interest (income)                                                             
  and interest                                         -4,200           -4,200  
  expense,                                                                      
  net                                                                           
  Adjusted EBITDA                                $    -35,000    $     -30,000  
                                                                                
                                                                                
                        PROCEPT BioRobotics Corporation                         
                                                                                
                                                                                
                     CONDENSED CONSOLIDATED BALANCE SHEETS                      
                                                                                
                           (Unaudited, in thousands)                            
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash equivalents      $             218,369    $            286,503  
  Accounts receivable, net                     105,030                  83,533  
  Inventory                                     81,410                  70,694  
  Prepaid expenses and other                                                    
  current                                        9,381                   9,648  
  assets                                                                        
  Total current assets                         414,190                 450,378  
  Restricted cash,                               3,038                   3,038  
  non-current                                                                   
  Property and equipment, net                   30,165                  30,399  
  Operating lease                               16,373                  17,538  
  right-of-use assets, net                                                      
  Intangible assets, net                           502                     709  
  Other assets                                   9,491                   6,019  
  Total assets                   $             473,759    $            508,081  
  Liabilities and                                                               
  Stockholders' Equity                                                          
  Current liabilities:                                                          
  Accounts payable               $              16,721    $             17,285  
  Accrued compensation                          25,976                  23,175  
  Deferred revenue                              15,636                  13,048  
  Operating leases, current                      2,655                   2,214  
  Other current liabilities                      9,365                  10,073  
  Total current liabilities                     70,353                  65,795  
  Long-term debt                                51,767                  51,615  
  Operating leases,                             22,570                  24,654  
  non-current                                                                   
  Other non-current                                161                     147  
  liabilities                                                                   
  Total liabilities                            144,851                 142,211  
  Stockholders’ equity:                                                         
  Additional paid-in capital                 1,055,475               1,007,390  
  Accumulated other                                  5                      37  
  comprehensive gain                                                            
  Accumulated deficit                         -726,572                -641,557  
  Total stockholders’ equity                   328,908                 365,870  
  Total liabilities and                                                         
  stockholders’                  $             473,759    $            508,081  
  equity                                                                        
                                                                                
                                                                                
                        PROCEPT BioRobotics Corporation                         
                                                                                
                                                                                
                         REVENUE BY TYPE AND GEOGRAPHY                          
                                                                                
                           (Unaudited, in thousands)                            
                                                                                
            Three                              Nine                             
            Months                             Months                           
            Ended                              Ended                            
            Septem…                            Septe…                           
            30,                                30,                              
  U.S.      2026               2025            2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  System                                                                        
  sales     $        24,689    $     24,747    $        77,141    $     65,400  
  and                                                                           
  renta…                                                                        
  Handp…                                                                        
  and                53,861          44,411            145,247          125,6…  
  other                                                                         
  consu…                                                                        
  Servi…              7,275           4,754             18,875          12,723  
  Total                                                                         
  U.S.               85,825          73,912            241,263          203,7…  
  reven…                                                                        
  Outsi…                                                                        
  of                                                                            
  U.S.                                                                          
  System                                                                        
  sales               4,503           3,391             11,756          10,179  
  and                                                                           
  renta…                                                                        
  Handp…                                                                        
  and                 6,974           5,316             20,175          15,805  
  other                                                                         
  consu…                                                                        
  Servi…                989             708              2,728           1,896  
  Total                                                                         
  outsi…                                                                        
  of                 12,466           9,415             34,659          27,880  
  U.S.                                                                          
  reven…                                                                        
  Total     $        98,291    $     83,327    $       275,922    $     231,6…  
  reven…                                                                        
                                                                                
                                                                                
                        PROCEPT BioRobotics Corporation                         
                                                                                
                                                                                
                   QUARTERLY U.S. INSTALL BASE AND PROCEDURES                   
                                                                                
                           (Unaudited, in thousands)                            
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.